I was essentially frying from the inside
In the chambers of Parliament, a woman who once faced two-percent odds of survival placed before lawmakers the quiet catastrophe that follows a medical crisis when the system turns away: Penny Taylor, who lost both legs to meningococcal septicaemia in 2009, has spent fifteen years navigating a recovery the health system largely left her to fund and manage alone. Her testimony, alongside the grief of a father whose daughter died from the same disease, has renewed pressure on New Zealand's public health institutions to widen vaccine access and build meaningful aftercare for those who survive. The question being asked is not only how to prevent meningitis, but what a society owes to those it has already failed to protect.
- A disease that can kill within hours is still reaching people who have no idea how fast it moves — forty cases in the past two years alone, and each one a potential tragedy unfolding before awareness can intervene.
- Māori and Pasifika communities face four to five times the risk of contracting meningitis, yet the free vaccination program excludes most of them, creating a protection gap that falls hardest on those already underserved.
- Pharmac's advisory committee has recommended against universal free vaccination for 13-25-year-olds, citing limited resources, while two new funding applications sit under review with no timeline for resolution.
- Penny Taylor raised the equivalent of a house deposit to travel to Australia for surgery the New Zealand system would not provide — a stark measure of how completely survivors are left to rebuild their lives without structured support.
- The Health Minister has requested information on survivor services, and the Health Select Committee has signaled continued scrutiny, suggesting policy movement may be closer than it has been — but for those already living with the aftermath, the waiting is its own burden.
Penny Taylor thought she had caught a stomach bug. By the time her mother found her unconscious in November 2009, meningococcal bacteria had already begun destroying her from within. Doctors in Palmerston North gave her thirty minutes to live and a two-percent chance of survival. Her young children were brought in to say goodbye. She was placed in an induced coma, her organs failing, her body swollen and darkening as the infection spread across her skin.
She woke a month later. What followed was, in some ways, harder than the crisis itself. Multiple surgeries — tissue removal, skin grafts, the amputation of both legs below the knee — were performed in a plastics ward far from her home. Every transfer between hospitals for dialysis sent pain through her damaged skin. When she was finally discharged, the support ended almost entirely. No physiotherapy, no recovery plan, no pathway forward. A young mother in a wheelchair, she returned to work because she had no other option.
The prosthetics the health system provided aggravated her wounds. So she raised enough money to travel to Australia for osteo-integration surgery — a procedure not available to her in New Zealand — and eventually walked again. She rebuilt her life largely through her own determination and financial sacrifice.
On a Wednesday in May, Taylor told this story to Parliament's Health Select Committee. Beside her in spirit was Gerard Rushton of the Meningitis Foundation, whose teenage daughter died from the disease in 2014. He described a vaccination program that leaves out the very communities most at risk: Māori and Pasifika people are four to five times more likely to contract meningitis, yet free vaccines are restricted to those in close-quarters settings like university halls. Everyone else pays $150 per dose for a multi-shot course.
The Foundation applied to Pharmac in 2022 for universal free vaccination of all 13-25-year-olds. Pharmac's advisory committee recommended declining it, citing limited resources and a preference for targeted coverage. Two new applications are now under review, but no decisions have been made. Medical advisors acknowledged that broader vaccination would be ideal if funding were unlimited — but it isn't.
The Health Minister has asked for a report on what support services exist for survivors. The committee has indicated it will keep examining vaccine funding. For Penny Taylor, the path forward is straightforward: wider prevention means fewer people walking the road she has walked. For now, that road remains longer and lonelier than it needs to be.
Penny Taylor thought she had picked up a stomach bug from her toddler's daycare. She was wrong. By the time her mother found her unconscious on a November afternoon in 2009, the meningococcal bacteria had already begun its work—a blood poisoning so aggressive that it would leave her a double-amputee and fundamentally reshape the next fifteen years of her life.
At the hospital in Palmerston North, the doctors gave her thirty minutes to live and a two percent chance of survival. Her three and seven-year-old children were brought in to say goodbye. Taylor's body had swollen to nearly twice its normal size, her skin darkening as the infection ravaged her organs. She was placed in an induced coma, her temperature climbing to 42 degrees. "I was essentially frying from the inside," she would later tell Parliament. The rash that had started as a small dot on her leg had spread across her entire body. All her organs had failed.
She woke a month later, against the odds. But survival, she discovered, was only the beginning of the ordeal. Unable to be transferred to a specialized facility in Waikato, she was sent to Lower Hutt's plastics ward, where she underwent multiple surgeries—debriding dead tissue, skin grafting, and ultimately the amputation of both legs below the knee. The month following her awakening was, she said, the most torturous part of the entire journey. She was transported between hospitals for dialysis, every bump in the road sending waves of pain through her damaged skin. "Every single touch, I would feel," she recalled. "That was excruciating."
When she was finally discharged, the support stopped almost entirely. There was no aftercare, no physiotherapy, no structured plan for recovery. A young mother in a wheelchair with two children to care for, she had no choice but to return to work. The funded prosthetics the health system provided didn't work—the sockets aggravated her damaged skin. Desperate to reclaim her life, she raised what amounted to a house deposit to travel to Australia for innovative osteo-integration surgery, a procedure that allowed her to eventually walk again and return to full-time work. "I actually got my life back," she said. But she had done it largely alone, navigating a system that seemed to abandon survivors once the acute crisis had passed.
On a Wednesday in May, Taylor sat before the Health Select Committee and told her story. She was not alone in her frustration. Gerard Rushton, chairman of the Meningitis Foundation Aotearoa New Zealand, was there too. His teenage daughter had died from meningitis in 2014. He told the committee that awareness of the disease remained dangerously low, and that the current vaccination program was inequitable. Free vaccines were available only to 13-25-year-olds living in close quarters—university halls, boarding schools—but those most at risk were being left out. Māori and Pasifika populations were four to five times more likely to contract meningitis, yet they were underrepresented in the groups eligible for free protection. Those who didn't qualify faced paying $150 per dose for vaccines that required multiple shots for full protection.
The foundation had submitted an application to Pharmac in 2022 requesting universal free vaccination for all 13-25-year-olds. Pharmac's Immunisation Advisory Committee had recommended declining it, arguing that resources were limited and vaccination should be targeted at high-risk groups. David Hughes, Pharmac's director of advice and assessment, explained that the committee was reviewing feedback on that decision, and two new applications to expand vaccine access were being considered. But no final decisions had been made, and the process was moving slowly.
The debate revealed a tension at the heart of public health policy. Nikki Turner, principal medical advisor to the Immunisation Advisory Centre, acknowledged that if resources were unlimited, she would support expanding the program. But they weren't. The meningococcal vaccines were highly effective—around eighty percent—but protection waned after three to five years, meaning ongoing doses would be needed. Associate Minister of Health David Seymour argued that funding decisions had to remain with independent experts at Pharmac, not politicians, to avoid decisions driven by political campaigns rather than health value.
Yet the human cost of delay was undeniable. There had been forty cases of meningitis in 2024 and 2025, down from sixty-nine in 2022, but the disease still moved with terrifying speed. When it struck, treatment often came too late. For Taylor, the answer was clear: better awareness and wider vaccination could prevent others from walking the road she had traveled. "If we can raise the prevention," she said, "then people won't end up travelling the road that I have." The Health Minister had asked for information on what support services were available to survivors. The committee had signaled it would continue exploring vaccine funding. But for those living with the aftermath of meningitis, the waiting continued.
Citações Notáveis
As soon as I was out of hospital, everything stopped. I had no aftercare, I had no physiotherapy, I was there to fight for myself.— Penny Taylor, meningitis survivor, to the Health Select Committee
The underlying factor of most cases of meningitis in New Zealand is that people are simply not aware of it.— Gerard Rushton, chairman of the Meningitis Foundation Aotearoa New Zealand
A Conversa do Hearth Outra perspectiva sobre a história
Why does Penny Taylor's story matter now, sixteen years after she got sick?
Because she's forcing the system to confront what happens after survival. Meningitis is rare, but when it strikes, it's catastrophic. And then the person is left alone. That's the gap she's exposing.
The doctors gave her a two percent chance. What made her different?
She doesn't say. Luck, biology, her mother checking in at the right moment—all of it mattered. But the real question isn't why she survived. It's why, after surviving something that extreme, the health system essentially abandoned her.
She had to raise money for surgery in Australia. Isn't that what public health is supposed to prevent?
Yes. She did everything right—she survived, she recovered, she wanted to work again. But the prosthetics the system provided didn't work for her damaged skin. So she had to become an entrepreneur of her own recovery. That's a failure of aftercare.
What about the vaccine debate? That seems separate from her story.
It's not. Rushton's daughter died in 2014. If the vaccines had been more widely available, if awareness had been higher, she might still be alive. Taylor's fighting for better care for survivors. Rushton's fighting to prevent more survivors from being created in the first place. They're two sides of the same problem.
Pharmac says resources are limited. Is that a real constraint or an excuse?
It's real. But it's also a choice about what matters. Meningitis is rare, so the cost-benefit calculation says target only the highest-risk groups. But that means Māori and Pasifika kids who aren't in university halls don't get protected. Equity gets sacrificed for efficiency.
What happens next?
Pharmac is reviewing applications. The Health Minister is asking questions. But Taylor's been waiting sixteen years. The real test is whether the system moves faster than the disease does.